Clovis Oncology, Inc. short interest in 2022
In 2022, Clovis Oncology, Inc.'s disclosed short interest ran from 20.54% of shares outstanding on 14 Jan 2022 to 16.75% on 15 Dec 2022, a change of -3.79 percentage points. The year's high was 29.58% on 30 Jun 2022 and its low 15.03% on 31 Mar 2022, averaging 21.33% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 20.09 days on 31 Oct 2022. Full history: Clovis Oncology, Inc..
Cite this page
By year: 2018 · 2019 · 2020 · 2021 · 2022
2022 in figures
- Start of year
- 20.54% (14 Jan 2022)
- End of year
- 16.75% (15 Dec 2022)
- Change
- -3.79 pp
- High
- 29.58% (30 Jun 2022)
- Low
- 15.03% (31 Mar 2022)
- Average
- 21.33%
- Highest days to cover
- 20.09 (31 Oct 2022)
- SEC filings marked
- 8
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 20.54% | 6.76 | results (8-K) |
| 31 Jan 2022 | 21.51% | 5.27 | |
| 15 Feb 2022 | 21.24% | 6.04 | |
| 28 Feb 2022 | 19.64% | 6.39 | results (8-K), 10-K filed |
| 15 Mar 2022 | 18.79% | 6.43 | |
| 31 Mar 2022 | 15.03% | 1.00 | |
| 14 Apr 2022 | 20.28% | 1.23 | |
| 29 Apr 2022 | 19.26% | 5.99 | |
| 13 May 2022 | 25.21% | 3.43 | results (8-K), 10-Q filed |
| 31 May 2022 | 27.42% | 10.07 | |
| 15 Jun 2022 | 28.67% | 3.46 | |
| 30 Jun 2022 | 29.58% | 1.73 | |
| 15 Jul 2022 | 19.86% | 1.00 | |
| 29 Jul 2022 | 19.43% | 6.21 | |
| 15 Aug 2022 | 20.53% | 7.05 | 10-Q filed, results (8-K) |
| 31 Aug 2022 | 20.07% | 11.05 | |
| 15 Sep 2022 | 22.95% | 5.41 | |
| 30 Sep 2022 | 21.81% | 13.66 | |
| 14 Oct 2022 | 21.79% | 17.26 | |
| 31 Oct 2022 | 21.30% | 20.09 | |
| 15 Nov 2022 | 19.33% | 2.73 | 10-Q filed |
| 30 Nov 2022 | 19.65% | 14.40 | |
| 15 Dec 2022 | 16.75% | 2.44 |
See also: Clovis Oncology, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.